Abstract: A decolonization drug, a preparation method thereof and an application thereof. The decolonization drug is non-antibiotic, simple and convenient to use, and can be used systemically, and has more types of sterilization; The decolonization drug involved in the invention contains added special components, which can improve the bactericidal performance of the drug through the activator effect; The decolonization drug is suitable for use in adults and sensitive populations, including the elderly, pregnant women, infants, children, etc.; especially as a mucosal drug for nasal mucosa, oral mucosa, ocular mucosa, abdominal mucosa, genital mucosa, etc., and can also be used as a bactericidal drug in other medical fields, including diabetic foot, burns, surgical site infections (SSIs), etc.

Abstract: The present invention relates to a method to prepare pharmaceutical compositions of sugammadex, to pharmaceutical compositions of sugammadex and uniform pharmaceutical batches of said compositions.

Abstract: The present invention relates to propanediol monoacetate mononitrate as well as the use thereof as antimicrobial agent, in particular for cosmetic applications.

Abstract: The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to conventional iron sucrose compositions.

Abstract: In some embodiments, the disclosure provides a method of making a sterile lacosamide composition, the method comprising; (a) obtaining a composition comprising (i) about 5 mg/mL to about 20 mg/mL lacosamide, (ii) about 5 mg/mL to about 12 mg/mL sodium chloride, and (iii) water, (b) placing the composition of (a) into a glass vial, wherein the glass vial has an ammonium sulfate coating, (c) sealing the composition inside the glass vial; and (d) autoclaving the sealed glass vial of (c) at 121° C. at 15 lbs pressure for 15 minutes, wherein the pH of the composition in (d) is substantially the same as the pH of the composition after (a), and wherein the composition of (d) comprises less than about 0.2% (wt/wt) of Impurity A, Impurity B, Impurity C, Impurity D, Impurity E or Impurity F.

Abstract: The invention relates to a antimicrobial and cleansing composition consisting of a. a polymeric biguanide, and b. a metal ion chelating agent, and g. a solvent, wherein the ratio of a:b is between 0.75:2.25 and 1.25:2.25, or about 1:2, and optionally one or more of the following ingredients; c. a quaternary ammonium salt, d. at least one surfactant, e. a humectant and f. a gelling agent. The invention further relates to said composition for use in a treatment, prevention or reduction of a disease, disorder or condition related to microbials, or treatment, prevention or reduction of infection, or inflammation, or infected wounds, or inflamed wounds, or treatment, prevention or reduction of biofilms, or removal of necrotic tissue. A liquid flow system may be used for administration of the composition.

Abstract: According to aspects of the present invention, a peptide with any one sequence of SEQ ID NOS:1 to 3 exhibits high selective binding affinity to a target and the microcapsule has superior physicochemical stability. Therefore, the cosmetic composition containing the microcapsule linked to the peptide manifests high delivery efficiency of an active ingredient included in the capsule to target cells, thereby exhibiting superior skin-condition improvement effects.

Abstract: The present invention relates to a lozenge composition for controlled release of cannabinoids comprising; i) a master granule component comprising one or more solid particles and one or more cannabinoids reversibly associated with the one or more solid particles; and ii) an extragranular component blended with the master granule component comprising one or more extragranular sugar alcohols.

Abstract: A surfactant-free cosmetic composition is disclosed. The composition is a stable water in silicone oil (W/S) formulation containing a silicone oil phase portion and an aqueous phase portion, wherein the silicone oil phase portion contains an emollient having a pyrrolidone carboxylic acid group, oil-absorbing powder and silicone oil, and the aqueous phase portion contains 50 wt.% or more of water based on the total weight of the surfactant-free cosmetic composition. The composition may further contain a high content of vitamin C or a vitamin C derivative and has improved long term storage stability.

Abstract: Formulations containing pharmaceutical active agent, propellant, and water at least partially adsorbed on or absorbed within one or more nylon pellets or nylon components of, for example, an inhaler such as a metered dose inhaler. Canisters, typically sealed canisters, containing such formulations. Inhalers, such as metered dose inhalers, containing such canisters. Methods of making and using the same.

Abstract: The present invention relates to a technical field of pharmaceutical preparation, in particular to a preparation method of naltrexone implants, including the following steps: (1) dissolving naltrexone and polylactic acid in an organic solvent to form naltrexone microspheres, and drying; (2) placing the naltrexone microspheres in a heated tableting mold for tableting, and obtaining naltrexone implant tablets; (3) dissolving the polylactic acid in the organic solvent to obtain a coating solution, and placing the coating solution in a coating pool, and then immersing the naltrexone implant tablets in the coating solution, and drying in a suspended state.

Abstract: A method of selectively inhibiting pathogenic microbes includes: providing a compound that is functional as a selective antimicrobial having a structure of Formula 1, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof; and contacting a pathogenic microbe with the compound such that the pathogenic microbe is selectively inhibited; wherein: ring A is a cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or polycycle combination thereof; X is S, SO, or SO2; Y is a linker or bond; Z is CH, CR2, or N; Z1 is C or N to form an imidazopyridine; each Z2, Z3, or Z4 is independently CH, CR2, or N; each Z5 or Z6 is C or CH; each R1, R2, R3 and/or R4 is independently a substituent; m is 0, 1, 2, 3, or 4; and n is zero or a positive integer.

Abstract: A solid cosmetic composition contains cationic surfactant, a polyhydric C2-C6 alcohol, C8-C30 alcohol or C8-C30 carboxylic acid or salt and a starch fraction, a modified starch or a starch derivative and is used for hair care.